vimarsana.com

Latest Breaking News On - Steven seedhouse - Page 6 : vimarsana.com

Gene Editing Is Working Wall Street Is Taking Notice

Shares of Crispr Therapeutics are up 45% this year, compared with the Nasdaq Composite's 31% rise.

United statesSteven seedhouseRaymond jamesVertex pharmaceuticalsDrug administrationEuropean hematology associationWall streetCrispr therapeuticsNasdaq compositeNobel prize winningIntellia therapeuticsSaharan africanEditas medicineBeam therapeuticsBill alpert

FDA staff unsure NASH drug s modest benefits outweigh safety risks

BioPharma

United statesBrian skorneySteven seedhouseMichael yeeRaymond jamesMadrigal pharmaceuticalsIntercept pharmaceuticalsDrug administrationViking therapeuticsAkero therapeutics

Apellis reports strong start for new vision loss drug

BioPharma

Raymond jamesJon millerIveric bioSteven seedhouseAstellas pharmaDrug administrationDive briefApellis pharmaceuticalWall streetUmer raffat

Why InflaRx Stock Skyrocketed This Week

The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.

Guggenheim yatin sunejaRaymond jamesInflarx gohibicSteven seedhouseDrug administrationEmergency use authorizationYatin suneja

StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy

Nine analysts raise stock price targets for Apellis Pharmaceuticals after it wins the FDA's first approval for a geographic atrophy therapy.

Peter steinRaymond jamesIveric bioAnnabel samimySteven seedhouseYigal nochomovitzRobertw bairdLaura chicoChris howertonChirinjeev kathuriaDoug tsaoColleen kusyTazeen ahmadJackk allenBrian culleyIb chemoprotection

vimarsana © 2020. All Rights Reserved.